Loading…
Employees: 1,500
Size Procter & Gamble Health (PGHL.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $971M, the 604th largest of 1,058 India companies the cockpit tracks. Shares closed at ₹5,556 on 6 Nov 2026.
Performance Over six months the shares gained 4.4%, against -13.9% for the median peer and 0.0% for the India market (cap-weighted) — 3rd highest of 19 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +2.4%); the operating margin is 30.8% (peer median 4.5%).
Valuation It trades at 24.7× forward earnings against a peer median of 24.4× (4th most expensive of 10).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +9%, so the hurdle is -4 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 86.6 points above its cost of capital (9.8% WACC).
Next results Next results expected around 3 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹14.1B | ₹14.1B | ₹12.5B | ₹12.3B | ₹11.1B |
| Revenue growth | — | +13% | +1% | +11% | — |
| Gross profit | ₹7.97B | ₹7.03B | ₹6.12B | ₹5.64B | ₹5.08B |
| EBITDA | ₹4.57B | ₹4.64B | ₹4.32B | ₹3.29B | ₹2.71B |
| Net income | ₹3.27B | ₹3.27B | ₹3.13B | ₹2.29B | ₹1.93B |
| Free cash flow | n/a | ₹3.33B | ₹1.67B | ₹2.08B | ₹1.41B |
| Capital expenditure | n/a | ₹155M | ₹85.6M | ₹425M | ₹379M |
| Total debt | ₹72.1M | ₹92.9M | ₹76.2M | ₹120M | ₹28.3M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PGHL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.2% | -7.3% | 5th highest of 20 |
| 6-month return | +4.4% | -13.9% | 3rd highest of 19 |
| Distance from 52-week high | -20.3% | -34.0% | 4th highest of 21 |
| Revenue growth (TTM) | +13.0% | +2.4% | 6th highest of 18 |
| Operating margin | 30.8% | 4.5% | 2nd highest of 18 |
| Forward P/E | 24.7× | 24.4× | 4th most expensive of 10 |
| Growth the price implies (Req g, 7 yrs) | 5.5% | 11.0% | 4th least demanding of 11 |
| Growth delivered (Del g) | +9.3% | +6.0% | 5th highest of 11 |
| Hurdle (Req g minus delivered) | -3.8 pp | +6.4 pp | 4th least demanding of 11 |
| ROIC minus cost of capital | +86.6 pp | -2.2 pp | 2nd highest of 16 |
| EV / EBITDA | 19.4× | 13.2× | 4th most expensive of 8 |
| Net debt / EBITDA | -0.7× | 2.1× | 3rd least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Procter & Gamble Health PGHL.NS | India | $971M | +4% | +13% | 31% | 24.7× | 5.5% | +9.3% |
| Kissei Pharmaceutical 4547.T | Japan | $973M | -16% | +6% | 6% | 12.0× | n/a | n/a |
| Strides Pharma Science STAR.NS | India | $973M | -13% | +11% | 14% | 15.5× | 18.1% | +7.8% |
| Jiangsu Yahong Meditech 688176.SS | China | $973M | -12% | +15% | -172% | n/a | n/a | n/a |
| MoonLake Immunotherapeutics MLTX | United States | $981M | -32% | n/a | n/a | n/a | n/a | n/a |
| Zhejiang Garden Biopharmaceutical 300401.SZ | China | $983M | -7% | +2% | 24% | 24.4× | 10.2% | +13.4% |
| SSY 2005.HK | Hong Kong | $990M | +10% | -4% | 12% | 13.0× | 2.1% | -0.5% |
| Immatics IMTX | United States | $952M | -44% | -65% | -556% | n/a | n/a | n/a |
| Savara SVRA | United States | $992M | -8% | n/a | n/a | n/a | n/a | n/a |
| Northeast Pharmaceutical 000597.SZ | China | $948M | -10% | -6% | 3% | n/a | -6.8% | -0.7% |
| Harbin Gloria Pharmaceuticals 002437.SZ | China | $999M | -15% | -16% | 13% | n/a | 8.8% | -6.9% |
| City Therapeutics CTY | United States | $944M | n/a | +388% | -442% | n/a | n/a | n/a |
| Hunan Warrant Pharmaceutical 688799.SS | China | $942M | -20% | +5% | 9% | 33.8× | n/a | n/a |
| KPC Pharmaceuticals 600422.SS | China | $1.00B | -7% | -41% | -10% | n/a | n/a | n/a |
| Harrow HROW | United States | $1.01B | -30% | +21% | 2% | 21.9× | 51.8% | +41.0% |
| Nxera Pharma 4565.T | Japan | $932M | +63% | +24% | 14% | 24.5× | 16.2% | +27.3% |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $930M | -24% | -6% | 5% | 41.1× | 33.2% | +4.2% |
| Dezhan Healthcare 000813.SZ | China | $928M | -18% | -10% | -121% | n/a | n/a | n/a |
| Oscotec 039200.KS | South Korea | $1.02B | -30% | +233% | 62% | 56.8× | -9.5% | +18.1% |
| Guangxi Wuzhou Zhongheng 600252.SS | China | $1.03B | -11% | -43% | -42% | n/a | 11.9% | -13.7% |
| Symbiotec Pharmalab SYMBIOTEC.NS | India | $1.03B | n/a | n/a | n/a | n/a | n/a | n/a |